PTPRB Loss-of-function

CI-VAR-00002530Explore in graph →CIViC 819

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Angiosarcoma2
PTPRB Loss-of-function	(diagnostic)	Diagnostic	B	Supports Positive	3	accepted	EID10079 A cohort of angiosarcomas (n=36) was sequenced and revealed to contain recurrent mutations in PTPRB (10/36) which were predominantly truncating or splice variants which impact the tyrosine phosphotase… (full text at CIViC) PMID 24633157 · Behjati et al., 2014 · Open in CIViC	civic
PTPRB Loss-of-function	Sunitinib + VatalanibSubstitutes	Predictive	D	Supports Sensitivity Response	3	accepted	EID1895 The endothelial phosphatase PTPRB, a negative regulator of vascular growth factor tyrosine kinases, harbored truncating mutations in 10 of 39 angiosarcomas (26%) which correlated with MYC amplificatio… (full text at CIViC) PMID 24633157 · Behjati et al., 2014 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.